Aptamer D3P-21
Aptamer spezifisch für kastrationsresistenten Prostatakrebs.
High affinity Aptamer
Easy to produce
High plasma half-life
Excellent tumor selectivity
The Aptamer of the present invention may be used for diagnostic or therapeutic purposes. In particular when coupled to a drug, the Aptamer may be used in analogy to an antibody-drug-conjugate.
The inventors used an orthotopic xenograft mouse model to perform an in vivo selection in order to identify an aptamer that selectively binds to cells of a hormone refractory prostate tumour. Several rounds of selection starting from a DNA library yielded an aptamer that binds to tumour tissue in vivo and to PC3 cells in vitro. The Aptamer is characterized in a PEGylation pattern that stabilizes the Aptamer and prolongs plasma half-life.
Licensing
21/01/2019 00:00:00
Patent application
5463
德国
